Forms of HRT: Patches, Pills, Gels, Rings

Educational only. Not medical advice. The choice of HRT delivery route affects risk profile, convenience, and cost. This decision should be made with a licensed clinician based on your individual health history and preferences.

The delivery route you choose for HRT is not just a matter of convenience. It can be the difference between a blood clot risk that doubles and one that does not change at all. Oral estrogen passes through the liver and increases clotting factor production. Transdermal estrogen bypasses the liver entirely. Same hormone, fundamentally different safety profile.

That one fact should be part of every prescribing conversation, and it frequently is not. Many clinicians default to oral estrogen because it is what they learned first, not because it is the best choice for the woman sitting in front of them. Understanding the delivery options and their tradeoffs helps you ask the right questions before the prescription is written.

• Transdermal estrogen (patches, gels) carries lower VTE risk than oral estrogen because it bypasses liver first-pass metabolism - this is not a minor difference, it is clinically significant
• Oral estradiol is the most commonly prescribed form and costs as little as $4/month at Walmart - for women without VTE risk factors, it is a practical first choice
• Vaginal estrogen treats local symptoms (dryness, urinary issues) without significant systemic absorption and is safe for many women who cannot use systemic HRT, including some breast cancer survivors
• The “best” route is the one that fits your risk profile, symptoms, lifestyle, and budget - not the one your clinic happens to stock
• Route can be changed during treatment if the first choice does not work

Products: estradiol tablets (Estrace, generics), conjugated equine estrogens (Premarin). Dosing: once daily. Cost: generic estradiol $4 to 15 per month; brand Premarin $30-100+/month.

The case for oral: simplest administration in the HRT toolkit - swallow a pill. Widest generic availability, lowest cost, and the most clinician experience behind it. For women without VTE risk factors who need to minimize medication costs, generic oral estradiol at $4 to 15 per month is hard to beat.

The case against oral: first-pass liver metabolism increases production of clotting factors, triglycerides, and certain binding proteins. VTE risk roughly doubles compared to non-use. Not the right choice for women with obesity (BMI 30+), VTE history or family history, active smoking, migraines with aura, or gallbladder disease. Nausea is more common than with other routes.

Products: Climara (weekly), Vivelle-Dot (twice-weekly), generic patches. Cost: $15 to 80 per month generic; $50 to 150 per month brand.

The case for patches: bypass the liver, which means lower VTE risk, less triglyceride effect, and less impact on clotting factors. Steady hormone delivery without the daily peaks and troughs of oral dosing. For women with any VTE risk factor, patches should be the default, not the alternative. Set-and-forget between changes.

The case against patches: skin irritation at the application site affects 10 to 20% of users. Adhesion problems in hot weather, during exercise, or with certain skin types. More expensive than generic oral. Some women dislike the visible patch, though placement in covered areas is standard. If adhesion is a problem, SkinTac (an OTC skin adhesive wipe, approximately $10 to 15) applied before the patch significantly improves adherence. Tegaderm transparent medical tape over the patch works as a backup.

Weekly vs twice-weekly: Climara (weekly) is more convenient but some women notice symptom return on days 6-7 before the next patch. Vivelle-Dot and generics (twice-weekly) provide more consistent levels with fewer end-of-patch dips. If you notice symptoms returning before your patch change day, switching from weekly to twice-weekly may solve the problem.

Products: EstroGel, Divigel, Evamist, Elestrin. Cost: $30 to 200 per month.

The case for gels: same liver-bypass benefit as patches without adhesion issues. More cosmetically discreet. Dose can be titrated precisely with some formulations.

The case against gels: daily application required (patches are less frequent). Transfer risk is real and serious - if a child or partner touches the application site before the product is fully absorbed, they can absorb estrogen through their own skin. The FDA has received reports of breast development in young children from estrogen transfer. Apply to areas covered by clothing, wash hands thoroughly after application, and wait 1 to 2 hours before skin contact at the site. Absorption varies more between individuals than with patches, which is why some clinicians check estradiol levels more frequently during initial titration.

Products: Vagifem/Yuvafem (tablets), Premarin cream, Estrace cream, Estring (ring), Imvexxy (insert). Cost: $30 to 200 per month.

The critical distinction: low-dose vaginal estrogen is a local treatment with minimal systemic absorption. It treats vaginal dryness, painful intercourse, urinary urgency, and recurrent UTIs without significantly raising blood estrogen levels. This matters because low-dose vaginal estrogen is safe for many women who cannot use systemic HRT, including some breast cancer survivors (per NAMS and ACOG guidance, discussed case-by-case with oncology). It does not require a progestogen for endometrial protection in most cases.

If you have genitourinary symptoms, vaginal estrogen should be discussed regardless of whether you use systemic HRT. Many women need both.

An increasingly popular approach: systemic estrogen (patch or gel for the VTE advantage) combined with a levonorgestrel IUD (Mirena) for endometrial protection. The IUD delivers progestogen directly to the uterus, providing local endometrial protection without the systemic progestogen effects that some women find intolerable - bloating, mood changes, breast tenderness.

This is off-label for HRT endometrial protection but has growing clinical support and is used routinely by many menopause specialists. The advantages are meaningful: it eliminates daily progesterone pills, avoids systemic progestogen side effects, and may carry lower breast cancer risk than systemic progestogen (though long-term data specific to this use is limited).

• Given my health history and risk factors, which route do you recommend and why?
• If I have VTE risk factors, should I specifically avoid oral estrogen?
• What is the cost difference between routes with my insurance?
• Can I switch routes later if the first choice does not work for me?
• Do I need systemic HRT, local vaginal estrogen, or both?